Ignios

Ignis Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for central nervous system (CNS) disorders in the Chinese market. Launched in 2021 through a strategic partnership between SK Biopharmaceuticals and 6 Dimensions Capital, the company possesses a robust pipeline of CNS assets, including cenobamate for epilepsy and solriamfetol for sleep disorders. Ignis aims to address significant unmet medical needs in neurology and psychiatry by leveraging its relationship with SK Biopharmaceuticals and its strong local expertise in China. The company's lead programs are currently in late-stage clinical development or undergoing regulatory review in China, positioning it as a major player in the regional CNS therapeutic landscape.